Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
ZIOP va subiendo hoy un +17%
http://www.google.com/finance?q=ziop&ei=DKgaUajDAcaXwQOiBQ
"ZIOPHARM Oncology Inc. (NASDAQ:ZIOP). The Company announced that the Phase 3 trial of palifosfamide in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. The Company will announce topline results from this trial during the last week of March 2013."
Recordad que ZIOP tiene un producto de quimio convencional contra sarcoma, no es competencia directa de TH-302 que trabaja sobre hipoxia